Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18438664 | MATERIALS AND METHODS FOR PURIFYING DNA, RNA, AND POLYPEPTIDES | February 2024 | March 2025 | Abandon | 13 | 2 | 0 | Yes | No |
| 18477609 | TOPICAL COMPOSITIONS DESIGNATED TO MAINTAIN AND/OR RESTORE THE INTEGRITY OF THE MUCOSA AND DAMAGED EPIDERMIS | September 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18460637 | APPLICATION OF HYALURONIC ACID IN PREPARING MEDICINES FOR PREVENTING OR TREATING FERROPTOSIS-RELATED DISEASES | September 2023 | December 2024 | Allow | 16 | 4 | 0 | No | No |
| 18459507 | COMPOSITION COMPRISING MANNOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING SAME AND USE THEREOF | September 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18354837 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | July 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18346935 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18336436 | ANTIBODY DRUG CONJUGATES | June 2023 | September 2024 | Allow | 16 | 0 | 0 | No | No |
| 18322767 | SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASE | May 2023 | April 2025 | Allow | 23 | 1 | 0 | No | No |
| 18313671 | TREATMENT OF A BACTERIAL VAGINAL INFECTION | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18308842 | C-MANNOSIDE COMPOUNDS USEFUL FOR THE TREATMENT OF URINARY TRACT INFECTIONS | April 2023 | June 2025 | Allow | 26 | 2 | 0 | No | No |
| 18301845 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18135609 | Nicotinyl Riboside Compounds and Their Uses | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18299303 | MALTODEXTRIN AND PROCESS OF MAKING SAME | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18131727 | METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOF | April 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18131192 | DIAGNOSTIC DRUG, DIAGNOSTIC METHOD AND DIAGNOSTIC DEVICE FOR PERMEABILITY OF INTESTINAL MUCOSA | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18130212 | SILICON CONTAINING DETECTABLE COMPOUNDS | April 2023 | February 2025 | Allow | 22 | 2 | 0 | No | No |
| 18180900 | Nanofibrillated Cellulose Fibers | March 2023 | June 2025 | Allow | 28 | 2 | 1 | No | No |
| 18176609 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | March 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18170167 | CONJUGATED OLIGONUCLEOTIDES | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18156511 | SELECTIVELY CONTROLLABLE CLEAVABLE LINKERS | January 2023 | August 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18155730 | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | January 2023 | February 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18062105 | METHOD FOR PRODUCING A POLYPHENOLIC COMPOSITION FROM BARLEY MALT | December 2022 | October 2024 | Allow | 22 | 1 | 0 | No | No |
| 18056008 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 18055579 | OLIGONUCLEOTIDE SYNTHESIZER | November 2022 | January 2025 | Abandon | 26 | 2 | 0 | No | No |
| 17960966 | COMPOSITIONS AND METHODS THAT ATTENUATE COGNITIVE AGING IN INDIVIDUALS WHO DO NOT HAVE DEMENTIA | October 2022 | February 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 17947716 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | September 2022 | October 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17931491 | METHODS AND COMPOSITIONS TO PREVENT AND TREAT INFLAMMATION AND ALLERGIC REACTIONS | September 2022 | February 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17941835 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17939896 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | September 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17850467 | PROTON ACTIVATED ATOMIC MEDICINE | June 2022 | February 2025 | Allow | 32 | 2 | 1 | No | No |
| 17722513 | CD73 INHIBITORS | April 2022 | January 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17658547 | METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS | April 2022 | August 2024 | Allow | 28 | 2 | 0 | No | No |
| 17674032 | ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USE | February 2022 | January 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17633895 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | February 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17633941 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | February 2022 | May 2025 | Allow | 39 | 1 | 0 | No | No |
| 17500099 | ANALOGUES OF OLEUROPEIN AND OLEACEIN AND USES THEREOF | October 2021 | February 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17494320 | REGULATION OF DNA SYNTHESIS BY NUCLEOTIDES LINKED TO PROTECTING GROUPS | October 2021 | May 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17598040 | SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM | September 2021 | March 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17367115 | OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | July 2021 | October 2024 | Abandon | 40 | 4 | 0 | No | No |
| 17351169 | Targeting Ligands | June 2021 | December 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17293370 | COMBINATION OF GOLD COMPLEXES WITH OLAPARIB OR OTHER PARP1/2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER RESISTANT TO SAID PARP1/2 INHIBITORS | May 2021 | January 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17317614 | LOW-DOSE TRIPLE COMBINATION FORMULATION | May 2021 | May 2025 | Abandon | 48 | 4 | 0 | Yes | No |
| 17285253 | STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF YEAST-DERIVED POLYSACCHARIDE INDUCING TREG CELL | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17278958 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | March 2021 | November 2024 | Allow | 44 | 1 | 0 | No | No |
| 17269182 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ISOLATION | February 2021 | November 2024 | Allow | 45 | 2 | 0 | No | No |
| 17267666 | NOVEL GINSENOSIDE AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | February 2021 | January 2024 | Allow | 36 | 2 | 0 | No | No |
| 17265794 | ANTIBIOTIC RESISTANCE-MODIFYING TRICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | February 2021 | May 2025 | Allow | 52 | 4 | 0 | No | No |
| 16972456 | NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION | December 2020 | July 2024 | Allow | 44 | 2 | 0 | No | No |
| 17050424 | ABCB5 LIGANDS AND SUBSTRATES | October 2020 | June 2025 | Allow | 56 | 3 | 1 | No | No |
| 17049742 | NUCLEIC ACID ISOLATION AND INHIBITOR REMOVAL FROM COMPLEX SAMPLES | October 2020 | May 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 17011880 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | September 2020 | December 2024 | Allow | 52 | 3 | 1 | No | No |
| 16999483 | METHOD OF PRODUCTION | August 2020 | November 2024 | Abandon | 51 | 3 | 0 | No | No |
| 16997255 | METHODS OF PROTECTING AN ORGAN USING TETRAHYDROCURCUMIN AND PHOSPHATIDYLCHOLINE | August 2020 | February 2023 | Abandon | 30 | 4 | 0 | No | Yes |
| 16844522 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | April 2020 | June 2025 | Abandon | 60 | 9 | 0 | Yes | Yes |
| 16647377 | GALNAC DERIVATIVES | March 2020 | August 2022 | Abandon | 29 | 9 | 0 | No | No |
| 16781987 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | February 2020 | December 2024 | Allow | 58 | 6 | 1 | Yes | No |
| 16726073 | HIGHLY ACCURATE DE NOVO POLYNUCLEOTIDE SYNTHESIS | December 2019 | March 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16612753 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | November 2019 | January 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16562358 | Immunomodulating Compounds and Related Compositions and Methods | September 2019 | April 2025 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 15847258 | DEUTERIUM-ENRICHED HYALURONAN | December 2017 | April 2019 | Allow | 16 | 0 | 0 | Yes | No |
| 15551531 | METHOD FOR ISOLATION OF POLYSACCHARIDES | August 2017 | January 2019 | Allow | 17 | 0 | 0 | No | No |
| 15537869 | ANTIBACTERIAL COMPOSITION CONTAINING AN ISOMER MIXTURE OF MONOSACCHARIDE ALKYL MONOACETALS OR MONOETHERS | June 2017 | August 2019 | Allow | 26 | 2 | 0 | No | No |
| 15619936 | MANGIFERIN-6-O-BERBERINE SALT AND PREPARATION METHOD AND USE THEREOF | June 2017 | March 2019 | Allow | 21 | 2 | 0 | Yes | No |
| 15533361 | SYNTHESIS OF MONOETHERS OF SUGAR COMPRISING A LONG ALKYL CHAIN AND USES THEREOF AS A SURFACTANT | June 2017 | July 2019 | Allow | 25 | 1 | 0 | Yes | No |
| 15602020 | METHODS FOR INTRODUCING MANNOSE 6-PHOSPHATE AND OTHER OLIGOSACCHARIDES ONTO GLYCOPROTEINS AND APPLICATIONS THEREOF | May 2017 | March 2019 | Allow | 21 | 1 | 0 | No | No |
| 15514520 | PHARMACEUTICAL COMPOSITIONS FOR TREATING EBOLA VIRUS DISEASE | March 2017 | March 2019 | Allow | 24 | 2 | 0 | Yes | No |
| 15352256 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | November 2016 | September 2019 | Allow | 34 | 3 | 0 | No | No |
| 15338805 | THERAPY-ENHANCING GLUCAN | October 2016 | January 2019 | Allow | 27 | 2 | 0 | Yes | No |
| 15119880 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | August 2016 | September 2018 | Allow | 25 | 2 | 0 | Yes | No |
| 15200086 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS | July 2016 | July 2019 | Allow | 36 | 3 | 0 | Yes | No |
| 15179103 | PHOSPHONATED POLYSACCHARIDES AND GELS AND PROCESS FOR MAKING SAME | June 2016 | December 2018 | Allow | 30 | 2 | 0 | Yes | No |
| 15093594 | HYALURONIC ACID AND ITS USE FOR TREATING VENOUS INSUFFICIENCY AND VARICOSE VEINS | April 2016 | October 2021 | Abandon | 60 | 13 | 1 | No | No |
| 14420911 | PROCESS OF PREPARING AN ESTERIFIED CELLULOSE ETHER IN THE PRESENCE OF AN ALKALI METAL CARBOXYLATE AND AN ALIPHATIC CARBOXYLIC ACID | February 2015 | May 2020 | Allow | 60 | 5 | 0 | No | Yes |
| 13632582 | Osmoprotective Complexes for Prevention of Mitochondrial Free Radical Damage Related Skin Aging | October 2012 | January 2013 | Allow | 4 | 0 | 0 | Yes | No |
| 13451613 | PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | April 2012 | August 2013 | Allow | 16 | 1 | 0 | No | No |
| 13496116 | POLYMER SUPPORT | March 2012 | February 2013 | Allow | 11 | 1 | 0 | Yes | No |
| 13326147 | SYNTHETIC HEPARIN DISACCHARIDES | December 2011 | January 2013 | Allow | 13 | 1 | 0 | No | No |
| 13271134 | HSP90 INHIBITORS | October 2011 | August 2013 | Allow | 22 | 1 | 0 | No | No |
| 13198593 | COMPOSITIONS COMPRISING NORIBOGAINE AND AN EXCIPIENT TO FACILITATE TRANSPORT ACROSS THE BLOOD BRAIN BARRIER | August 2011 | March 2014 | Allow | 32 | 1 | 1 | No | No |
| 13183222 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG ANALOGS | July 2011 | January 2014 | Allow | 30 | 1 | 1 | No | No |
| 13183275 | 11-AZA, 11-THIA AND 11-OXA STEROL COMPOUNDS AND COMPOSITIONS | July 2011 | April 2013 | Allow | 22 | 1 | 0 | No | No |
| 13159875 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYLOXY)-PHENYL] HEXANE | June 2011 | August 2011 | Allow | 2 | 0 | 0 | Yes | No |
| 13103960 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | May 2011 | October 2011 | Allow | 5 | 2 | 0 | Yes | No |
| 13102451 | Compounds and Combinations | May 2011 | March 2013 | Allow | 22 | 1 | 1 | Yes | No |
| 12990214 | NOVEL TRIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | February 2011 | May 2013 | Allow | 31 | 1 | 0 | No | No |
| 13015805 | OSMOPROTECTIVE COMPLEXES FOR PREVENTION OF INTRA-CELLULAR DEHYDRATION IN MAMMALS | January 2011 | September 2012 | Allow | 20 | 0 | 0 | Yes | No |
| 13015882 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | January 2011 | June 2013 | Allow | 29 | 1 | 0 | Yes | No |
| 13015980 | GALACTOSYLATED PRO-DRUGS OF NON-STEROIDAL ANTI-INFLAMMATORIES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS AND REDUCED TOXICITY OF THE STARTING DRUG | January 2011 | May 2013 | Allow | 28 | 1 | 0 | Yes | No |
| 12999325 | METHOD FOR SEPARATION OF DOUBLE-STRANDED AND SINGLE-STRANDED NUCLEIC ACIDS FROM THE SAME SAMPLE | December 2010 | September 2013 | Allow | 33 | 1 | 0 | Yes | No |
| 12966070 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | December 2010 | April 2013 | Allow | 28 | 1 | 0 | No | No |
| 12993764 | METHOD FOR TREATING AND PREVENTING KIDNEY STONES EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | November 2010 | August 2013 | Allow | 33 | 2 | 0 | No | No |
| 12993750 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | November 2010 | March 2014 | Allow | 40 | 3 | 0 | No | No |
| 12993766 | METHOD FOR TREATING HYPONATREMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | November 2010 | April 2013 | Allow | 29 | 2 | 0 | No | No |
| 12889980 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | September 2010 | June 2013 | Allow | 32 | 2 | 0 | No | No |
| 12883498 | ORAL COMPOSITIONS FOR ABSORPTION OF PHOSPHOROUS COMPOUNDS | September 2010 | April 2013 | Allow | 31 | 1 | 0 | No | No |
| 12933013 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | September 2010 | January 2013 | Allow | 28 | 1 | 0 | No | No |
| 12854603 | THERAPY-ENHANCING GLUCAN | August 2010 | August 2013 | Allow | 37 | 3 | 0 | Yes | No |
| 12853786 | METHODS OF USE OF BIOMATERIAL AND INJECTABLE IMPLANT CONTAINING BIOMATERIAL | August 2010 | February 2013 | Allow | 30 | 1 | 0 | No | No |
| 12853753 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial | August 2010 | February 2013 | Allow | 30 | 1 | 0 | No | No |
| 12853775 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial | August 2010 | February 2013 | Allow | 30 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OLSON, ERIC.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OLSON, ERIC works in Art Unit 1693 and has examined 273 patent applications in our dataset. With an allowance rate of 89.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner OLSON, ERIC's allowance rate of 89.7% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by OLSON, ERIC receive 2.28 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by OLSON, ERIC is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.1% benefit to allowance rate for applications examined by OLSON, ERIC. This interview benefit is in the 26% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 27.3% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.8% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 77.4% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 31.9% are granted (fully or in part). This grant rate is in the 25% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 20.1% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.